188 related articles for article (PubMed ID: 19374404)
21. Rapid assembly of matrix metalloprotease inhibitors using click chemistry.
Wang J; Uttamchandani M; Li J; Hu M; Yao SQ
Org Lett; 2006 Aug; 8(17):3821-4. PubMed ID: 16898826
[TBL] [Abstract][Full Text] [Related]
22. Low molecular weight inhibitors of matrix metalloproteinases can enhance the expression of matrix metalloproteinase-2 (gelatinase A) without inhibiting its activation.
Kerkvliet EH; Jansen ID; Schoenmaker TA; Docherty AJ; Beertsen W; Everts V
Cancer; 2003 Mar; 97(6):1582-8. PubMed ID: 12627524
[TBL] [Abstract][Full Text] [Related]
23. Expression of various matrix proteases and Ets family transcriptional factors in ovarian cancer cell lines: correlation to invasive potential.
Nishikawa A; Iwasaki M; Akutagawa N; Manase K; Yamashita S; Endo T; Kudo R
Gynecol Oncol; 2000 Nov; 79(2):256-63. PubMed ID: 11063654
[TBL] [Abstract][Full Text] [Related]
24. High-resolution solution structure of the catalytic fragment of human collagenase-3 (MMP-13) complexed with a hydroxamic acid inhibitor.
Moy FJ; Chanda PK; Chen JM; Cosmi S; Edris W; Levin JI; Powers R
J Mol Biol; 2000 Sep; 302(3):671-89. PubMed ID: 10986126
[TBL] [Abstract][Full Text] [Related]
25. Effects of Shugansanjie Tang on matrix metalloproteinases 1, 3 and 9 and telomerase reverse transcriptase expression in human breast cells in vitro.
Loo WT; Chen JP; Chow LW; Chou JW
Biomed Pharmacother; 2007 Oct; 61(9):601-5. PubMed ID: 17913446
[TBL] [Abstract][Full Text] [Related]
26. Anti-HIV drugs decrease the expression of matrix metalloproteinases in astrocytes and microglia.
Liuzzi GM; Mastroianni CM; Latronico T; Mengoni F; Fasano A; Lichtner M; Vullo V; Riccio P
Brain; 2004 Feb; 127(Pt 2):398-407. PubMed ID: 14662518
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the pharmacology of hydroxamate- and carboxylate-based matrix metalloproteinase inhibitors (MMPIs) for the treatment of osteoarthritis.
Janusz MJ; Hookfin EB; Brown KK; Hsieh LC; Heitmeyer SA; Taiwo YO; Natchus MG; Pikul S; Almstead NG; De B; Peng SX; Baker TR; Patel V
Inflamm Res; 2006 Feb; 55(2):60-5. PubMed ID: 16612565
[TBL] [Abstract][Full Text] [Related]
28. "One-step" detection of matrix metalloproteinase activity using a fluorogenic peptide probe-immobilized diagnostic kit.
Ryu JH; Lee A; Lee S; Ahn CH; Park JW; Leary JF; Park S; Kim K; Kwon IC; Youn IC; Choi K
Bioconjug Chem; 2010 Jul; 21(7):1378-84. PubMed ID: 20575580
[TBL] [Abstract][Full Text] [Related]
29. Expression of matrix metalloproteinases and their endogenous tissue inhibitors in skin lesions from patients with tuberous sclerosis.
Papakonstantinou E; Dionyssopoulos A; Aletras AJ; Pesintzaki C; Minas A; Karakiulakis G
J Am Acad Dermatol; 2004 Oct; 51(4):526-33. PubMed ID: 15389186
[TBL] [Abstract][Full Text] [Related]
30. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.
Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Chen L; Dunaway CM; Gu F; Mieling GE
J Med Chem; 1999 Jan; 42(1):87-94. PubMed ID: 9888835
[TBL] [Abstract][Full Text] [Related]
31. In vivo migration of transplanted myoblasts requires matrix metalloproteinase activity.
El Fahime E; Torrente Y; Caron NJ; Bresolin MD; Tremblay JP
Exp Cell Res; 2000 Aug; 258(2):279-87. PubMed ID: 10896779
[TBL] [Abstract][Full Text] [Related]
32. Synthetic matrix metalloproteinase inhibitor decreases early cardiac neural crest migration in chicken embryos.
Cai DH; Brauer PR
Dev Dyn; 2002 Aug; 224(4):441-9. PubMed ID: 12203736
[TBL] [Abstract][Full Text] [Related]
33. Galloyl cyclic-imide derivative CH1104I inhibits tumor invasion through suppressing matrix metalloproteinase activity.
Chen MH; Cui SX; Cheng YN; Sun LR; Li QB; Xu WF; Ward SG; Tang W; Qu XJ
Anticancer Drugs; 2008 Nov; 19(10):957-65. PubMed ID: 18827560
[TBL] [Abstract][Full Text] [Related]
34. Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas.
Allen C; McDonald C; Giannini C; Peng KW; Rosales G; Russell SJ; Galanis E
J Gene Med; 2004 Nov; 6(11):1216-27. PubMed ID: 15459967
[TBL] [Abstract][Full Text] [Related]
35. Effect of phorbol ester and cytokines on matrix metalloproteinase and tissue inhibitor of metalloproteinase expression in tumor and normal cell lines.
Mackay AR; Ballin M; Pelina MD; Farina AR; Nason AM; Hartzler JL; Thorgeirsson UP
Invasion Metastasis; 1992; 12(3-4):168-84. PubMed ID: 1284126
[TBL] [Abstract][Full Text] [Related]
36. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells.
O-charoenrat P; Modjtahedi H; Rhys-Evans P; Court WJ; Box GM; Eccles SA
Cancer Res; 2000 Feb; 60(4):1121-8. PubMed ID: 10706134
[TBL] [Abstract][Full Text] [Related]
37. Hydroxamate-based peptide inhibitors of matrix metalloprotease 2.
Jani M; Tordai H; Trexler M; Bányai L; Patthy L
Biochimie; 2005; 87(3-4):385-92. PubMed ID: 15781326
[TBL] [Abstract][Full Text] [Related]
38. Significant differences in the matrix metalloproteinase expression profiles of spontaneous medulloblastomas/primitive neuroectodermal tumors as compared with their xenografted, established tumor cell line derived counterparts.
Bodey B; Bodey B; Siegel SE; Kaiser HE
In Vivo; 2000; 14(5):675-82. PubMed ID: 11212845
[TBL] [Abstract][Full Text] [Related]
39. Repression of matrix metalloproteinase gene expression by ginsenoside Rh2 in human astroglioma cells.
Kim SY; Kim DH; Han SJ; Hyun JW; Kim HS
Biochem Pharmacol; 2007 Dec; 74(11):1642-51. PubMed ID: 17880928
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of gelatinolytic activity in tumor tissues by synthetic matrix metalloproteinase inhibitor: application of film in situ zymography.
Ikeda M; Maekawa R; Tanaka H; Matsumoto M; Takeda Y; Tamura Y; Nemori R; Yoshioka T
Clin Cancer Res; 2000 Aug; 6(8):3290-6. PubMed ID: 10955815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
